A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents

Susan D Mathias, Xiaoyan Li, Melissa Eisen, Nancy Carpenter, Ross D Crosby, Victor S Blanchette, Susan D Mathias, Xiaoyan Li, Melissa Eisen, Nancy Carpenter, Ross D Crosby, Victor S Blanchette

Abstract

Background: Chronic immune thrombocytopenia (ITP) in children can negatively impact their health-related quality of life (HRQoL) and impose a burden on their parents. This study sought to examine the effect of romiplostim on HRQoL and parental burden in children with primary ITP.

Procedure: This was a phase 3, randomized, double-blind, placebo-controlled study. Children aged <18 years with ITP ≥6 months were randomly assigned to receive romiplostim or placebo for 24 weeks. The Kids' ITP Tool (KIT) was used to measure HRQoL and was administered to patients and/or their parents at baseline and weeks 8, 16, and 25. Mean KIT scores at each assessment and mean changes in KIT scores from baseline were calculated overall by treatment group and platelet response status. Psychometric properties of the KIT were evaluated and the minimally important difference (MID) was estimated for different KIT versions.

Results: Sixty-two patients (42 romiplostim and 20 placebo) were enrolled. Changes in KIT scores by treatment group showed numerically greater and more often statistically significant improvements from baseline to each assessment for children receiving romiplostim versus placebo. Mixed-effects analysis demonstrated statistically significantly greater reduction in parental burden from baseline in the romiplostim group versus placebo. Ranges for the MID were estimated as 9-13 points for the Child Self-Report version and 11-13 points for the Parent Impact version.

Conclusions: The treatment with romiplostim may be associated with improved HRQoL in children with primary ITP and reduced burden to their parents.

Keywords: health-related quality of life; kids’ ITP tools; minimally important difference; parental burden; pediatric immune thrombocytopenia; romiplostim.

© 2016 The Authors. Pediatric Blood & Cancer, published by Wiley Periodicals, Inc.

References

    1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995–1008.
    1. Kuhne T. Immune thrombocytopenia (ITP), 2nd ed London, Boston: UNI‐MED Verlag Bremen; 2013.
    1. Rodeghiero F, Ruggeri M. ITP and international guidelines: What do we know, what do we need? Presse Med 2014;43(4 Pt 2):e61–e67.
    1. Imbach P, Akatsuka J, Blanchette V, Burek‐Kozlowska A, Bussel J, Gaedicke G, Gianella‐Borradori A, Gugler E, Hirt A, Imholz B, McMillan R, Morell A, Newland A, Nugent D, Schoni MH, Wagner HP. Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 1995;154(9 Suppl 4):S60–S64.
    1. Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: Retrospective and prospective survey in Germany. Semin Thromb Hemost 2001;27(3):253–267.
    1. Zeller B, Rajantie J, Hedlund‐Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, Henter JI, Nopho ITP. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr 2005;94:178–184.
    1. Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K, Wesenberg F. Immune thrombocytopenic purpura in childhood in Norway: A prospective, population‐based registration. Pediatr Hematol Oncol 2000;17:551–558.
    1. Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, Fryzek J, Kaye JA. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol 2010;149:855–864.
    1. Bennett CM, Tarantino M. Chronic immune thrombocytopenia in children: Epidemiology and clinical presentation. Hematol Oncol Clin North Am 2009;23:1223–1238.
    1. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 2003;55:107–111.
    1. Rajantie J, Zeller B, Treutiger I, Rosthoj S, group NIw, five national studying. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007;25:1838–1840.
    1. Klaassen RJ, Blanchette VS, Barnard D, Wakefield CD, Curtis C, Bradley CS, Neufeld EJ, Buchanan GR, Silva MP, Chan AK, Young NL. Validity, reliability, and responsiveness of a new measure of health‐related quality of life in children with immune thrombocytopenic purpura: The Kids' ITP tools. J Pediatr 2007;150:510–515.
    1. Heitink‐Polle KM, Haverman L, Annink KV, Schep SJ, de Haas M, Bruin MC. Health‐related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica 2014;99:1525–1531.
    1. Del Vecchio GC, De Santis A, Accettura L, De Mattia D, Giordano P. Chronic immune thrombocytopenia in childhood. Blood Coagul Fibrinolysis 2014;25:297–299.
    1. Garzon AM, Mitchell WB. Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Front Pediatr 2015;3:70.
    1. Kime C, Klima J, Rose MJ, O'Brien SH. Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children's hospitals. Pediatrics 2013;131:880‐885.
    1. Kuhne T, Berchtold W, Michaels LA, Wu R, Donato H, Espina B, Tamary H, Rodeghiero F, Chitlur M, Rischewski J, Imbach P, Intercontinental Cooperative ITPSG . Newly diagnosed immune thrombocytopenia in children and adults: A comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011;96:1831–1837.
    1. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6‐month, randomised, phase 3 study. Lancet 2011;377:393–402.
    1. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Jr. , Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double‐blind randomised controlled trial. Lancet 2008;371:395–403.
    1. Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V. Pilot study of the effect of romiplostim on child health‐related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer 2012;58:395–398.
    1. Barnard D, Woloski M, Feeny D, McCusker P, Wu J, David M, Bussel J, Lusher J, Wakefield C, Henriques S, Blanchette V, Canadian Children's Platelet Study G . Development of disease‐specific health‐related quality‐of‐life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol 2003;25:56–62.
    1. Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. A phase 3, randomized, double‐blind, placebo‐controlled study to determine the safety and efficacy of romiplostim in children with immune thrombocytopenia (ITP). Blood 2015;126:7.
    1. Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. Effect of romiplostim on health‐related quality of life in children with immune thrombocytopenia and associated burden in their parents: Results from a phase 3, randomized, double‐blind, placebo‐controlled study. Abstract Presented at 57th American Society of Hematology Annual Meeting, Orlando, FL, Dec 4–8, 2015. Blood 2015. 126:37.
    1. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40.
    1. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed Hillsdale, NJ: Lawrence Erlbaum; 1988.
    1. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease‐specific quality of life in clinical trials. CMAJ 1986;134:889–895.
    1. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: The lesson of Cronbach. J Clin Epidemiol 1997;50:869–879.
    1. Bussel JB, PcGd Miguel, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, GrW Chan, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): A randomised, multicentre, placebo‐controlled study. Lancet Haematol 2015;2:e315–e325.
    1. Klaassen RJ, Blanchette V, Burke TA, Wakefield C, Grainger JD, Gaedicke G, Riedlinger A, Dufort G, Citrin E, Reguerre Y, Pellier I, Curtis C, Young NL. Quality of life in childhood immune thrombocytopenia: International validation of the kids' ITP tools. Pediatr Blood Cancer 2013;60:95–100.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera